The Pennsylvania Society of Oncology and Hematology represents more than 200 physicians and other health care professionals who care for cancer patients. The Society is a non-profit corporation devoted to the improvement of hematologic and oncologic care of patients.

Membership in the Society is open to physicians, allied health professionals, and institutions with a demonstrated interest and involvement in the care of patients with hematologic and oncologic disorders. It is also open to residents and fellows who are actively enrolled in a full-time residency program in hematology or oncology in Pennsylvania or who are in an appropriate fellowship program. Corporate entities involved in the care and treatment of cancer patients may also become members.

The site provides resources for cancer patients, including a searchable database of Society members for those individuals seeking an oncologist, hematologist, surgical oncologist, or radiation oncologist.

The Pennsylvania Society of Oncology and Hematology is grateful to our Corporate Sponsors, whose donations help us fulfill our mission.

Tenacious approach helps this physician get policymakers on board

The AMA Wire┬« “Members Move Medicine” series profiles a wide variety of doctors, offering a glimpse into the passions of women and men navigating new courses in American medicine.

On the move with: Marilyn J. Heine, MD, a physician in emergency medicine and hematology-oncology in active clinical practice in southeast Pennsylvania.

Continue Reading


Important Changes Coming to Novitasphere Log In Requirements

Novitas, the Medicare Administrative Contractor (MAC) for Jurisdictions H and Jurisdiction L, has announced important changes to Novitasphere, their free internet portal.

Click Here for Additional Information

Join PSOH at the
Best of ASCO in Philadelphia

July 28 & 29 at the Philadelphia Hilton – City Avenue

Special Deep-Discounted Registration Fees for PSOH Members

Click Here for Additional Information

Apply for ASCO’s
Health Policy Leadership
Development Program

Applications are now open for the 2019-2020 ASCO Health Policy Leadership Development Program (HP-LDP). Formerly the Health Policy Fellowship Program, the HP-LDP is a one-year program that provides an opportunity for ASCO members to develop expertise in health policy, advocacy, and grassroots activity.

Participants will also be full members of the ASCO Leadership Development Program, which focuses on building expertise in health policy, while also gaining valuable leadership skills and mentorship from ASCO leaders. This could be a great way to get leadership training for your up-and-coming local leaders.

The HP-LDP is open to all ASCO members in the United States who completed their final subspecialty training between 2009 and 2014.

Array BioPharma’s Encorafenib & Binimetinib Approved by FDA

As a member of PSOH we are sharing the following information from our Corporate Member, Array BioPharma, Inc’s recent FDA approval.

Array BioPharma Inc., is pleased to announce that the U.S. Food and Drug Administration has approved encorafenib (BRAFTOVI™) capsules, and binimetinib (MEKTOVI┬«) tablets, as an oral combination therapy for patients with unresectable or metastatic melanoma with a BRAF V600E/K mutation as detected by an FDA-approved test. BRAFTOVI is not indicated for the treatment of patients with wild-type BRAF melanoma.

Click here to read the full press release

Full Prescribing information is available at: www.braftovimektovi.com

For additional information, please contact Bentley Boivin, Access Account Director at Array BioPharma at 518-441-8080 or email Bentley.boivin@arraybiopharma.com.


Our Corporate Members

Pennsylvania Society of Oncology and Hematology
777 East Park Drive, PO Box 8820
Harrisburg, PA 17105-8820
(717) 558-7750 phone
(717) 558-7841 fax

This website brought to you by:

Website design by Sister Webs Design Studio, where 5% of profits are donated to women's cancer funds

Our Corporate Members